Thank you so much. It was a very inspiring meeting, many achievements, new ideas and team work against gastric cancer 🔝🔝💪

🇪🇸 ¡Próximamente! El proyecto europeo AIDA para combatir el cáncer gástrico, organiza un curso gratuito con 3 webinars enfocados a la "Prevención del cáncer gástrico". 📅 Cuándo: 12.06, 19.06, 26.06 💻Regístrate: linktr.ee/AIDA_EU

🔬 A Korean study (n >900,000) shows H. pylori eradication reduces gastric cancer incidence & mortality — even in those >70. 📉 Prevention works at any age. 📍 The earlier, the better. 📄 Jung et al., Gastroenterology 2025 📎 doi.org/10.1053/j.gast…

The AIDA EU project is launching a free #Spanish-language webinar series to address the rise of gastric cancer cases in 🇪🇺. The first session focus is on the "Epidemiology of #GastricCancer". 🗓️ When: June 12 🕒 Moderator: Dr. Tania Fleitas 💻 digestivecancers-eu.zoom.us/webinar/regist… 🗣️ 🇪🇸

The Georgian Registry of #HelicobacterPylori Management 🇬🇪 is LIVE! Led by Dr. Jaba Zarkua — hepatologist, researcher & award-winning novelist 📚🩺 🌍 Georgia becomes the 39th European country in the #HpRegistry project!🦠👏

No te lo pierdas!. Regístrate gratis Aegastro Hp-EuReg 💊 Organización Panamericana de Gastroenterología

🔝 News!! The Egyptian Registry of #HelicobacterPylori Management #HpEgyptReg 🇪🇬 is running!👏👏 Dr. Mohamed Alboraie M.D., FRCP, hepatologist, researcher, and Executive Director of Egypt’s presidential hepatitis initiative, leads this🆕 subproject of the #WorldRegistry 🌍⚕️

🚨 ¡Ya comienza el webinar AIDA! Diagnóstico y tratamiento de Helicobacter pylori Con Martínez, Tejedor y Sánchez Modera J.P. Gisbert ¡Gracias por unirse! Hp-EuReg 💊 Hospital Clínic

🔍 La próxima semana cierra nuestra serie de webinars AIDA Tema: Lesiones precursoras del cáncer gástrico 🕑 14h (España) Con Cuatrecasas, Fernández-Esparrach y Moreira Modera: L. Moreira ¡Te esperamos!

📢 We’re thrilled to welcome the Thai Registry of #HelicobacterPylori Management (#HpThailandReg) 🇹🇭 to the #WorldRegistry! 🌏 Led by Prof. Ratha-korn Vilaichone of Thammasat Univ., expert in H. pylori, gastric cancer & GI bleeding. Great step for digestive health! 👏

Os esperamos Aegastro Organización Panamericana de Gastroenterología Hp-EuReg 💊 Servei Gastroenterologia Hospital Clínic Barcelona

🦠 H. pylori estará relacionada con 11 millones de cánceres gástricos en los próximos años. "Si erradicáramos la bacteria, evitaríamos la mayoría de estos tumores" entrevista a Javier P. Gisbert y otros expertos en el EL MUNDO 📖 elmundo.es/ciencia-y-salu… Aegastro Sociedad Española de Patología Digestiva (SEPD)

🇮🇪 H. pylori First-Line Treatment in Ireland (2013–2022) – #HpEuReg 🔹 Triple therapy (C+A): 88% 🔹 14-day Rx: ↑ 39%→99% 🔹 High-dose PPI: ↑ 37%→99% 🔹 Eradication: ↑ 75%→82% (still <90%) 🧪 Clarithro/Metro resistance >15% 🧱 BQT: 94% (underused) 📄 doi.org/10.3390/antibi…

Big congrats to Javier P. Gisbert ! His expertise and respected voice in the field make this interview a must-read. 📰 ⚠️Don’t miss it! #HpEuReg

🆕🆕🆕‼️ 🇵🇹 H. pylori First-Line Treatment in Portugal (2013–2022) – #HpEuReg 🔹 Triple therapy (C+A): ↓ 29%→0% 🔹 Bismuth quadruple (B+M+Tc+PPI): ↑ to 76% in 2022 🔹 Best regimens: Concomitant-CAM & BMTc = >91% success 🔹 Overall: 87% eradication 📄 doi.org/10.1159/000543…

🎉Great news! Our researchers have co-authored a new paper in BMJ Gut on the global challenge of Helicobacter pylori antibiotic resistance. #HpEureg Proud to see our team's work contributing to global health! 👏 gut.bmj.com/cgi/rapidpdf/g…

🧠 New AI system personalizes H. pylori treatment with 94.1% success (vs 88.1% standard care). Trained on 38k patients, externally validated. A key step toward AI-driven gastric cancer prevention. #HpEuReg 👉 Read the full paper: nature.com/articles/s4146…

🦠 Rising H. pylori antibiotic resistance calls for smarter treatments. New studies + real-world data from Hp-EuReg 💊 highlight the need for tailored therapy, resistance testing & guideline-based care. Precision matters!

🌍🆕 European data from #HpEuReg: In 13,787 patients, 10-day single-capsule bismuth quadruple therapy (Sc-BQT) was more effective and better tolerated than 14-day concomitant therapy (CT) for H. pylori eradication. Game-changer in first-line treatment🔬 Doi: 10.1111/apt.70261

🇨🇭Swiss study (Hp-EuReg) shows high effectiveness & safety of 1st-line H. pylori treatments: 🔍49% used amoxicillin-clarithromycin triple therapy, most others got 10-day bismuth quadruple therapy. Both regimens performed well. #HpEuReg DOI: doi.org/10.57187/s.419.